Health, biotech and agriculture

Anhui Zhifei Longcom智飞龙科马

Standard profile, compiled by hefei.be from public sourcesvaccinesinfluenza vaccineCOVID-19 vaccinebiopharma

About the company

Anhui Zhifei Longcom is the Hefei vaccine research and production base of Chongqing Zhifei Biological Products, which acquired it in 2008. With the Chinese Academy of Sciences’ Institute of Microbiology it developed a recombinant protein COVID-19 vaccine that received emergency-use approval in China in March 2021, and in 2025 it launched a quadrivalent influenza vaccine. Its plants are in the Hefei High-tech Zone.

Video

No video yet. A company video is an add-on for companies with a profile.

Presentation

No presentation yet. A company presentation is an add-on for companies with a profile.

News

No news yet. Once the company claims its profile, hefei.be follows the news on the company website and whatever the company approves appears here.

Partnerships on hefei.be

No confirmed partnerships yet. A partnership only appears once both companies confirm it.